Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment

Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir

(2015) Rong Liu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

(2015) Preethi Krishnan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hepatitis C virus drug resistance-associated substitutions: State of the art summary

(2015) Erik Lontok et al.   HEPATOLOGY

Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden

(2015) Ida Lindström et al.   Infectious Diseases

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

(2015) Jürgen K Rockstroh et al.   Lancet HIV

In VitroActivity and Resistance Profile of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus

(2014) J. P. Bilello et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

(2014) Michael Manns et al.   LANCET

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

(2014) Mark S. Sulkowski et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

(2014) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

(2013) Fiona McPhee et al.   HEPATOLOGY

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients

(2013) Stefania Paolucci et al.   Virology Journal

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

(2013) Min Gao   Current Opinion in Virology

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

(2012) Yoshiyasu Karino et al.   JOURNAL OF HEPATOLOGY

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

(2012) Yoshiyuki Suzuki et al.   JOURNAL OF HEPATOLOGY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE